<DOC>
	<DOCNO>NCT01379729</DOCNO>
	<brief_summary>Primary outcome measurement parameter functional beta cell mass 6 month PT . Functional beta-cell mass calculate use AUC/min 150 160 min hyperglycemic clamp 180 mg/dl . The investigator hypothesize functional beta-cell mass 20 % compare healthy control . Secondary outcome measurement : Functional beta-cell mass 2,12,18,24,36,48 60 month PT . The investigator also compare 2 , 6,12 , 24,36,48 60 month change base-line ( base-line = first intraperitoneal transplantation ) : - metabolic control - safety parameter - episode hypoglycemia - islet cell autoantibody , lymphocyte subset , T-cell reactivity auto- alloantigens use pre-transplant measurement base-line The investigator hypothesize metabolic control prevalence hypoglycemia , significantly improve till PT month 12 . Histopathology biopsy specimen human intraperitoneal beta cell implant , time second implant . Comparison composition graft , identification microenvironment host origin correlation functional assessment perform .</brief_summary>
	<brief_title>Bet Cell Therapy Diabetes Type 1</brief_title>
	<detailed_description>In recipient loss long-term function intraportal implantation ( Group A ) 1 . To implant alginate embed human beta cell graft `` therapeutic '' dose intraperitoneal cavity type 1 diabetic patient immunosuppression tacrolimus/MMF . 2 . To obtain histopathology biopsy specimen intraperitoneal human beta cell implant . 3 . To assess safety profile , metabolic immune effect alginate embed implant intraperitoneal cavity . In patient candidate islet cell transplantation ( Group B ) 4 . To implant alginate embed human beta cell graft `` therapeutic '' dose intraperitoneal cavity type 1 diabetic patient immunosuppression tacrolimus/MMF . 5 . To obtain histopathology biopsy specimen intraperitoneal human beta cell implant 6 . To assess safety profile , metabolic immune effect alginate embed implant intraperitoneal cavity .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Group A : Patients loss longterm function intraportal implantation ( Patients type 1 insulindependent diabetes receive two intraportal implantation &gt; 12 month ago . Random Cpeptide 0.09 0.5 ng/dl ( glycemia 100 200 mg/dl ) Cooperative reliable patient give informed consent signature Group B : Patients candidate islet cell transplantation age 1865 year , male female , Caucasian ; subject &lt; 50 yr allocate rituximab treatment arm body weight &lt; 100 kg ; patient bodyweight &lt; 80kg , receive priority patient BMI ≤ 27 kg/m2 receive priority Type 1 insulindependent diabetes Cpeptide &lt; 0.07 nmol/l ( &lt; 0.2 µg/l ) 6 min . glucagon IV ( 1mg ) ( glycemia &gt; 180 mg/dl ) Intensive insulin therapy two year , patient insulin pump least 2 month inclusion receive priority Patients least one follow chronic complication diabetes : albuminuria 301000mg/ 24hrs 3 separate determination ( &gt; 1 month ) outside episode illness , despite intake ACE inhibitor ; mean systolic blood pressure 130 mmHg mean diastolic blood pressure 85 mmHg , measure home ambulatory BP monitoring moderate severe nonproliferative proliferative retinopathy hypoglycemic unawareness Cooperative reliable patient give informed consent signature Women reproductive age Smoker EBV antibody negativity HIV 1 &amp; 2 antibody positivity CMV IgM positivity Hepatitis B infection GFR &lt; 45 ml/min/1.72 m2 Albuminuria ≥ 1000 mg/24 hrs History thrombosis pulmonary embolism History malignancy , tuberculosis chronic viral hepatitis History serious illness could relevant protocol Presence clinical significant HLA antibody Blood donation within one month prior screen Symptoms and/or sign infection , particularly ( present past ) endocarditis , osteomyelitis Any history hepatic neoplastic disease Any history renal disease ( except diabetes ) Abnormal liver function test and/or NMR liver Hemoglobinopathy History illness , opinion investigator , might confound result study pose additional risk patient Use illicit drug overconsumption alcohol ( &gt; 3 IU/day ) history drug alcohol abuse Being legally incapacitate , significant emotional problem time study , history psychiatric disorder may exacerbate transplantation procedure interfere compliance followup Having receive antidepressant medication last 6 month Participating another pharmacological study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Type 1 Diabetes</keyword>
	<keyword>Transplantation</keyword>
	<keyword>Beta Cells</keyword>
	<keyword>Encapsulation</keyword>
</DOC>